skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8830

A randomized study examining the effect of 3 SSRI on premature ejaculation using a validated questionnaire

(2548) Views  (522) Full article downloads

Authors: Mohamed Arafa, Rany Shamloul

Published Date October 2007 Volume 2007:3(4) Pages 527 - 531
DOI: http://dx.doi.org/10.2147/TCRM.S

Mohamed Arafa1,2, Rany Shamloul1

1Andrology department, Cairo University hospital, Cairo, Egypt; 2Dr Fakhry hospital, El-Khobar, Saudi Arabia

Aim: This study reports the results of a large prospective single-blinded clinical trial of 3 SSRI (paroxetine, fluoxetine and escitalopram) in PE using a validated questionnaire.

Methods: A total of 100 normally potent men suffering from PE were enrolled in a randomized single-blinded comparative study of fluoxetine, paroxetine and escitalopram. Patients were randomized into 3 treatment groups. Group 1 comprised 33 men who received fluoxetine 20 mg daily, group 2 comprised 37 men who received escitalopram 10 mg and group 3 comprised 30 men who received paroxetine 20 mg daily. All drug regimens were given in early morning dose and continued for 4 weeks.

Results: All 100 (100%) patients experienced a significant increase in their AIPE total score after drug treatment. There was no significant difference regarding any of the 7 items of the AIPE between the 3 treatment groups. All 3 drugs were generally well tolerated.

Conclusions: Our relatively large study, using a validated questionnaire confirmed similar useful effect of paroxetine, fluoxetine and escitalopram on ejaculation time. Further large cohort studies with long-term follow up are needed to evaluate the sustained effects of these drugs on ejaculation latency.








Readers of this article also read:

The therapeutic potential of escitalopram in the treatment of panic disorder
Clinical studies with oral lipid based formulations of poorly soluble compounds
Review of thalidomide in the treatment of newly diagnosed multiple myeloma
Treatment of premenstrual dysphoric disorder (PMDD) with a novel formulation of drospirenone and ethinyl estradiol
Therapeutical approach to plasma homocysteine and cardiovascular risk reduction
“One pill, once daily”: what clinicians need to know about Atripla™
Continuation treatment of major depressive disorder: is there a case for duloxetine?
Comparative efficacy of escitalopram in the treatment of major depressive disorder
Antianxiety medications for the treatment of complex agoraphobia: pharmacological interventions for a behavioral condition
Rapid improvement of depressive symptoms in suicide attempters following treatment with milnacipran and tricyclic antidepressants – a case series